Predictors of PPIUCD Discontinuation at Two Years: A Clinical Study in Pakistan (NCT06766396) | Clinical Trial Compass
CompletedNot Applicable
Predictors of PPIUCD Discontinuation at Two Years: A Clinical Study in Pakistan
Pakistan3,400 participantsStarted 2017-11-01
Plain-language summary
This prospective cohort study evaluated the continuation rates, complications, and satisfaction associated with postpartum intrauterine contraceptive devices (PPIUCDs) as a long-acting reversible contraception (LARC) method. Conducted in the Department of Obstetrics and Gynecology at Services Hospital, Lahore, Pakistan, from November 2017 to December 31, 2022, the study enrolled pregnant women attending antenatal care. Counseling was conducted using the GATHER technique, and informed consent was obtained before insertion. PPIUCDs were inserted postpartum during vaginal or cesarean deliveries by trained healthcare professionals. Follow-ups at 3, 6, 12, and 24 months assessed continuation rates, complications, and reasons for discontinuation.
Who can participate
Sex
FEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Pregnant women attending antenatal care at the Department of Obstetrics and Gynecology, Services Hospital Lahore.
* Willing to use postpartum intrauterine contraceptive device (PPIUCD) as a method of contraception.
* Provided informed consent for participation in the study.
* Delivered via vaginal delivery or cesarean section with no contraindications to PPIUCD insertion.
Exclusion Criteria:
* Known uterine anomalies or severe uterine bleeding post-delivery.
* Diagnosed with chorioamnionitis or puerperal sepsis during delivery or postpartum.
* Known hypersensitivity or contraindications to copper-based intrauterine devices.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
continuation rate of PPIUCD at 24 months.
Timeframe: 24 months post-insertion
Trial details
NCT IDNCT06766396
SponsorServices Institute of Medical Sciences, Pakistan